We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 267

California Governor Considers Drug Price Reporting Bill and Ban on Discounts and Rebates for Branded Pharmaceutical Products
  • Cooley LLP
  • USA
  • September 18 2017

The California State Legislature sent two new pharmaceutical pricing measures, S.B. 17 and A.B. 265, to Governor Jerry Brown on September 13th. S.B


U.S. Supreme Court Limits Venue Under the Patent Statute in TC Heartland
  • Paul Hastings LLP
  • USA
  • May 23 2017

On May 22, 2017, the United States Supreme Court, in TC Heartland LLC v. Kraft Foods Group Brands LLC, put an end to the swirling legal debate


Pharmaceutical & medical device regulatory update, vol. II, issue 6
  • Jones Day
  • USA
  • March 27 2015

A federal court in California has ruled that under the Biologics Price Competition and Innovation Act ("BPCI Act") a biosimilar applicant is not


California School Nurses Organization claiming districts violating Health & Safety Code for allowing non-nurses to administer some medications
  • Liebert Cassidy Whitmore
  • USA
  • August 29 2014

The California School Nurses Organization ("CSNO") has contacted a number of school districts asserting that only licensed healthcare providers may


California lists 4-Methylimidazole as a Proposition 65 carcinogen
  • Orrick, Herrington & Sutcliffe LLP
  • USA
  • February 10 2011

On January 7, 2011, OEHHA added to the Proposition 65 list of carcinogens 4- Methylimidazole, which is used in the manufacture of pharmaceuticals, photographic chemicals, dyes and pigments, cleaning and agricultural chemicals, rubber, and in certain food products including caramel coloring, soy sauce, Worcestershire sauce, wine, and ammoniated molasses.


California agency proposes NSRL for chemical common in foods after cooking
  • Shook Hardy & Bacon LLP
  • USA
  • January 14 2011

California EPA's Office of Environmental Health Hazard Assessment (OEHHA) has proposed a no significant risk level (NSRL) of 16 micrograms per day for 4-methylimidazole (4-MEI), a chemical commonly present in foods such as wine, soy sauce and Worcestershire sauce after they have been cooked.


4-MEI in your food and beverages? New label warning requirements may be needed
  • Alston & Bird LLP
  • USA
  • January 11 2011

On January 7, 2011, the state of California decided to list under Proposition 65 the chemical 4-methyl-imidazole (4-MEI), and proposed to establish a no significant risk level (NSRL) at 16 micrograms per day.


FTC files suit against dietary supplements that claimed to prevent diabetes
  • Manatt Phelps & Phillips LLP
  • USA
  • November 23 2010

The Federal Trade Commission filed a complaint in California federal court against Wellness Support Network, Inc., and two of its principals, alleging that the defendants made false claims that their dietary supplements can treat and prevent diabetes.


California Supreme Court precludes pass-on defense in Clayton Act claim and finds standing under the UCL
  • Hinshaw & Culbertson LLP
  • USA
  • July 12 2010

The Supreme Court of California today issued its decision in Clayworth v. Pfizer, Inc., addressing issues raised under California’s antitrust statute, The Clayton Act, and California’s Unfair Competition Law (“UCL”).


California appellate decision affirms right of health insurers to rescind policies for misrepresentation
  • Locke Lord LLP
  • USA
  • January 22 2010

The continuing debate about retroactive cancellation of individual health insurance policies in California has just been clarified.